Disclaimer. This site reads publicly available research papers and corporate filings and explains what they say. It is not investment advice and does not recommend buying or selling any security. Historical cases shown here are computed from public data; the sample sizes are small and are not a basis for prediction. We do not answer questions about individual stocks.
Readouts · Company page
Dong-A ST
Company facts
- Status
- KOSPI 170900 · ISIN KR7170900005
- Founded
- 2013-03-04
- CEO
- 정재훈
- Headquarters
- 서울 동대문구 용두동 138 ~255 천호대로 64
- Industry
- KSIC 212
- Fiscal year end
- 12
- Links
- Filings · DART · Quote · finance.naver.com · Website
- Source
- DART
Financial summary (from filings)
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue | 663,980 | 697,869 | 808,780 |
| Operating income | 11,178 | −25,002 | 623 |
| Net income | 2,021 | −23,235 | −37,611 |
| Total assets | 1,264,421 | 1,391,735 | 1,412,046 |
| Total liabilities | 581,113 | 682,927 | 740,397 |
| Total equity | 683,308 | 708,808 | 671,649 |
Unit: KRW million · Consolidated statements · Source DART 사업보고서
Figures are copied from the filing with only the unit changed. No growth rates or assessments are shown.
Readouts that mention this company
Dementia drug neflamapimod and CervoMed regulatory filing — when a company states "supported by a paper," three points are verified · Nature Neuroscience mouse study evaluation · 143 U.S. listed companies citing papers in 8-K filings · Tau-related national R&D
A clinical trial has been published tracking for one year whether weight loss persists after switching from the injectable weight-loss drugs Wegovy and Mounjaro to the pill form of Foundayo · Eli Lilly paper review · Chugai Pharmaceutical Japanese patent · D&D Pharmatech, Ildong Pharmaceutical, Hanmi Pharmaceutical status
National R&D projects (NTIS)
49
item
30,780,745,500
Cumulative government R&D funding (KRW)
Largest projects
- 미국의약품 승인기관의 인증을 위한 글로벌선도 천연물신약 개발 2013 · 산업통상자원부
- 천연물 파킨슨병 치료제 (DA-9805) 미국 임상 2상 완료 및 해외 기술이전 2016 · 산업통상자원부
- 천연물 파킨슨병 치료제 (DA-9805) 미국 임상 2상 완료 및 해외 기술이전 2017 · 산업통상자원부
Korean patent filings (KIPRIS)
116
item
Recently published patents
- TEAD 억제제로서의 바이사이클릭 헤테로사이클 화합물 20260630
- 용출률이 개선된 닌테다닙을 포함하는 정제 제형 20260323
- 아미노피리미딘 유도체의 결정다형 및 이의 제조방법 20260317
- 용해도가 개선된 AhR 조절제 화합물 20251210
- 아미노피리미딘 유도체 및 이의 아릴 탄화수소 수용체 조절제로서의 용도 20251021
Papers with affiliated authors (OpenAlex)
19
item
Companies in the same readouts
Last updated 2026-09-21